Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant disorder.
The disease has been formally characterized with epistaxis, cutaneous and mucosal telangiectases, a first-degree relative with HHT, and visceral lesions such as arteriovenous malformations (AVMs). Hereditary hemorrhagic telangiectasia has been underreported for many years.
Wider recognition of this disorder in recent years has prompted researchers and physicians to recognize milder cases and focus on earlier treatment.
This article highlights different treatments used to control epistaxis and screen for other complications associated with HHT.
2012-04-05
Eng.
Cutis; cutaneous medicine for the practitioner
Reid Clinic, Lackland Air Force Base, Texas, USA.
Cutis. 2012 Feb;89(2):69-72
© Galenicom 1999-2013